Bramble: NYU Langone Health https://news.ketelle.co.uk/entities/nyu-langone-health Stories involving NYU Langone Health, told neutrally, with how each side covers them. en-gb Phase 3 trial: sac-TMT cuts death risk by about a third in advanced endometrial cancer https://news.ketelle.co.uk/stories/nyu-langone-phase-3-trial-sacituzumab-tirumotecan-improves-outcomes-in https://news.ketelle.co.uk/stories/nyu-langone-phase-3-trial-sacituzumab-tirumotecan-improves-outcomes-in Mon, 26 Oct 2026 15:50:33 +0000 Health Results of a randomized phase 3 trial of sacituzumab tirumotecan (sac-TMT), developed by Merck and Kelun-Biotech, were presented in Madrid on 26 October. They show lower risks of progression and death than chemotherapy in advanced or recurrent endometrial cancer. (2 outlets: 0 left · 1 centre · 1 right)